TY - JOUR
T1 - Assessment of right ventricular function in the research setting
T2 - Knowledge gaps and pathways forward an official American thoracic society research statement
AU - Lahm, Tim
AU - Douglas, Ivor S.
AU - Archer, Stephen L.
AU - Bogaard, Harm J.
AU - Chesler, Naomi C.
AU - Haddad, Francois
AU - Hemnes, Anna R.
AU - Kawut, Steven M.
AU - Kline, Jeffrey A.
AU - Kolb, Todd M.
AU - Mathai, Stephen C.
AU - Mercier, Olaf
AU - Michelakis, Evangelos D.
AU - Naeije, Robert
AU - Tuder, Rubin M.
AU - Ventetuolo, Corey E.
AU - Vieillard-Baron, Antoine
AU - Voelkel, Norbert F.
AU - Vonk-Noordegraaf, Anton
AU - Hassoun, Paul M.
N1 - Funding Information:
Author Disclosures: T.L. served as a speaker for Bayer; served as a consultant for Actelion and Gilead; received research support from Eli Lilly, Gilead, and Pfizer; and served on an advisory committee for Gilead. I.S.D. served on an advisory committee for Accelerate Diagnostics. A.R.H. served as a consultant for Bayer, Actelion, United Therapeutics, and GlaxoSmithKline; served on an advisory committee for Actelion and United Therapeutics; received research support from United Therapeutics; and provided expert testimony for Pfizer. S.M.K. received travel support from Actelion, Bayer, Gilead, Lung Biotech, Mallinckrodt, and United Therapeutics. J.A.K. received research support from Ikaria, Janssen, and Pfizer; has a patent pending on fibrinolysis technology; and served on a steering committee for a clinical trial with Janssen and Bayer. S.C.M. served as a consultant for Bayer, Actelion, and Gilead; served on an advisory committee for Actelion; and received personal fees from United Therapeutics. E.D.M. served on an advisory committee for Medtelligence; and his institution served as a site for clinical trials for Bayer, Bellerophon, and United Therapeutics. C.E.V. served as a consultant for Acceleron, Bayer, United Therapeutics, and Maquet; received research support from Eiger, Actelion, and Pfizer; and served on an advisory committee for Actelion, Bayer, and United Therapeutics. A.V.-B. received travel support from GE Healthcare; and received grants and personal fees from GlaxoSmithKline. N.F.V. served as a consultant for Janssen and Actelion; and served on an advisory committee for Actelion. A.V.-N. served a speaker for Actelion and Merck Sharp & Dohme. P.M.H., S.L.A., H.J.B., N.C.C., F.H., T.M.K., O.M., R.N., and R.M.T. reported no relationships with relevant commercial interests.
Publisher Copyright:
© 2018 by the American Thoracic Society.
PY - 2018/8/15
Y1 - 2018/8/15
N2 - Background: Right ventricular (RV) adaptation to acute and chronic pulmonary hypertensive syndromes is a significant determinant of short- and long-term outcomes. Although remarkable progress has been made in the understanding of RV function and failure since the meeting of the NIH Working Group on Cellular and Molecular Mechanisms of Right Heart Failure in 2005, significant gaps remain at many levels in the understanding of cellular and molecular mechanisms of RV responses to pressure and volume overload, in the validation of diagnostic modalities, and in the development of evidence-based therapies. Methods: A multidisciplinary working group of 20 international experts from the American Thoracic Society Assemblies on Pulmonary Circulation and Critical Care, as well as external content experts, reviewed the literature, identified important knowledge gaps, and provided recommendations. Results: This document reviews the knowledge in the field of RV failure, identifies and prioritizes themost pertinent research gaps, and provides a prioritized pathway for addressing these preclinical and clinical questions. The group identified knowledge gaps and research opportunities in three major topic areas: 1) optimizing the methodology to assess RV function in acute and chronic conditions in preclinical models, human studies, and clinical trials; 2) analyzing advanced RV hemodynamic parameters at rest and in response to exercise; and 3) deciphering the underlying molecular and pathogenic mechanisms of RV function and failure in diverse pulmonary hypertension syndromes. Conclusions: This statement provides a roadmap to further advance the state of knowledge, with the ultimate goal of developing RV-targeted therapies for patients with RV failure of any etiology.
AB - Background: Right ventricular (RV) adaptation to acute and chronic pulmonary hypertensive syndromes is a significant determinant of short- and long-term outcomes. Although remarkable progress has been made in the understanding of RV function and failure since the meeting of the NIH Working Group on Cellular and Molecular Mechanisms of Right Heart Failure in 2005, significant gaps remain at many levels in the understanding of cellular and molecular mechanisms of RV responses to pressure and volume overload, in the validation of diagnostic modalities, and in the development of evidence-based therapies. Methods: A multidisciplinary working group of 20 international experts from the American Thoracic Society Assemblies on Pulmonary Circulation and Critical Care, as well as external content experts, reviewed the literature, identified important knowledge gaps, and provided recommendations. Results: This document reviews the knowledge in the field of RV failure, identifies and prioritizes themost pertinent research gaps, and provides a prioritized pathway for addressing these preclinical and clinical questions. The group identified knowledge gaps and research opportunities in three major topic areas: 1) optimizing the methodology to assess RV function in acute and chronic conditions in preclinical models, human studies, and clinical trials; 2) analyzing advanced RV hemodynamic parameters at rest and in response to exercise; and 3) deciphering the underlying molecular and pathogenic mechanisms of RV function and failure in diverse pulmonary hypertension syndromes. Conclusions: This statement provides a roadmap to further advance the state of knowledge, with the ultimate goal of developing RV-targeted therapies for patients with RV failure of any etiology.
KW - Acute respiratory distress syndrome
KW - Pulmonary circulation
KW - Pulmonary embolism
KW - Pulmonary hypertension
KW - Right ventricle
UR - http://www.scopus.com/inward/record.url?scp=85051522930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051522930&partnerID=8YFLogxK
U2 - 10.1164/rccm.201806-1160ST
DO - 10.1164/rccm.201806-1160ST
M3 - Review article
C2 - 30109950
AN - SCOPUS:85051522930
SN - 1073-449X
VL - 198
SP - e15-e43
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
IS - 4
ER -